| ID | 1217 |
| Name of the vaccine | ExPEC9V |
| Microbe | Bacteria |
| Disease name | E.coli Infections |
| Name of bacteria | Escherichia coli |
| Type of vaccine | Bioconjugate |
| Nucleic acid content | Circular duplex DNA |
| Age | 60 years and older |
| Description of the vaccine | 9-valent extraintestinal pathogenic Escherichia Coli vaccine. |
| Name of the manufacturer | Janssen Research & Development, LLC |
| Name of the manufacturing country | Australia, Canada, Denmark, Japan, Korea, Republic of, Netherlands, New Zealand, Spain, United Kingdom, United States. |
| Year of manufacture | 2027 |
| Clinical Phase status | Clinical - Phase 3 |
| Bacterial strain | Gram-negative, rod-shaped bacteria. |
| Efficacy | NA |
| Vaccine formulation | NA |
| Dosage | Single dose. |
| Mechanism of action | NA |
| Route of administration | Intramuscular |
| Indications | Prevents Invasive extraintestinal pathogenic Escherichia Coli disease (IED). |
| Export | NA |
| Approval | NA |
| Adjuvant | NA |
| Repurposing | NA |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | Single dose |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NCT04899336 |
| Reference | https://www.jnj.com/innovation/meet-janssen-researcher-working-on-human-e-coli-vaccine |
| Other name | NA |
| Additional Links | NA
|